Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 16, 2023

Lenvatinib Plus Pembrolizumab vs Sunitinib as First-Line Treatment for Advanced RCC

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Lancet Oncol 2023 Mar 01;24(3)228-238, TK Choueiri, M Eto, R Motzer, U De Giorgi, T Buchler, NS Basappa, MJ Méndez-Vidal, S Tjulandin, S Hoon Park, B Melichar, T Hutson, C Alemany, B McGregor, T Powles, V Grünwald, B Alekseev, SY Rha, E Kopyltsov, A Kapoor, T Alonso Gordoa, JC Goh, M Staehler, JR Merchan, R Xie, RF Perini, K Mody, J McKenzie, CG Porta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading